RoslinCT lands £7.25M Scottish grant to digitise cell therapy manufacturing

What's the deal? RoslinCTDealroom has a profile for this one. Try Dealroom →, a global cell therapy contract development and manufacturing organisation (CDMO), has been awarded an R&D grant of up to £7.25 million (≈$9.6 million) from Scottish Enterprise. The funding backs the company's multi-year plan to digitise its manufacturing operations in Scotland.

What's the endgame? The money funds a digitally integrated manufacturing environment, boosting operational efficiency, data connectivity, and AI capabilities across RoslinCT's operations. The aim: a more connected, data-driven setup that supports clients across the product lifecycle and helps bring cell therapies to patients faster and more cheaply.

Why now? Demand for advanced therapies is rising, and digital technologies are playing a bigger role in delivering scalable, efficient manufacturing. The project is also expected to create high-value jobs in Scotland's life sciences sector.

"Digital technologies are transforming how cell therapies are developed and manufactured, enabling greater efficiency, consistency and scalability," said chief executive officer Peter Coleman.

Scottish Enterprise chief executive Adrian Gillespie called the project "a prime example of how Scottish Enterprise support can enable innovation at scale and strengthen competitiveness in global markets."

The signal: The grant ranks in the top 3% by size among all UK health grants on record, a sample of more than 2,000. It underscores a policy bet that digitised, AI-enabled manufacturing — not just new therapies — will decide which countries stay competitive in cell and gene therapy.

Read more: markets.financialcontent.com

Image credit: Generated with Gemini